The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Antibiotic adjuvants – A strategy to unlock bacterial resistance to antibiotics
Open accessAbstract
Resistance to available antibiotics in pathogenic bacteria is currently a global challenge since the number of strains that are resistant to multiple types of antibiotics has increased dramatically each year and has spread worldwide. To unlock this problem, the use of an 'antibiotic adjuvant' in combination with an antibiotic is now being exploited. This approach enables us to prolong the lifespan of these life-saving drugs. This digests review provides an overview of the main types of antibiotic adjuvants, the basis of their operation and the remaining issues to be tackled in this field. Particular emphasis is placed on those compounds that are already in clinical development, namely β-lactamase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance-the need for global solutions
Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K. M., Wertheim, H. F. L., Sumpradit, N., Vlieghe, E., Hara, G. L., Gould, I. M., Goossens, H., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70318-9 · Cited by 4,439
Molecular mechanisms of antibiotic resistance
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. V. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3380 · Cited by 4,092
Antibiotic resistance is ancient
D’Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., et al. (2011) · Nature · doi:10.1038/nature10388 · Cited by 2,720
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Llor, C., & Bjerrum, L. (2014) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614554919 · Cited by 2,079
Molecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
Multidrug-resistance efflux pumps ? not just for resistance
Piddock, L. J. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1464 · Cited by 1,522
Carbapenems: Past, Present, and Future
Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-11 · Cited by 1,502
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Targeting virulence: a new paradigm for antimicrobial therapy
Clatworthy, A. E., Pierson, E., & Hung, D. T. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.24 · Cited by 1,406
Anti-virulence strategies to combat bacteria-mediated disease
Rasko, D. A., & Sperandio, V. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3013 · Cited by 1,373
Antibiotic tolerance facilitates the evolution of resistance
Levin-Reisman, I., Ronin, I., Gefen, O., Braniss, I., Shoresh, N., & Balaban, N. Q. (2017) · Science · doi:10.1126/science.aaj2191 · Cited by 1,251
Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria
Piddock, L. J. V. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.382-402.2006 · Cited by 1,231
Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.105-116.2001 · Cited by 903
Clavulanic Acid: a Beta-Lactamase-Inhibiting Beta-Lactam from Streptomyces clavuligerus
Reading, C., & Cole, M. (1977) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.11.5.852 · Cited by 739
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
The Impact of Antimicrobial Resistance on Health and Economic Outcomes
Eliopoulos, G. M., Cosgrove, S. E., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/375081 · Cited by 637
Combination approaches to combat multidrug-resistant bacteria
Worthington, R. J., & Melander, C. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.12.006 · Cited by 625
McMurry, L., Petrucci, R. E., & Levy, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3974 · Cited by 604
Antibiotic Adjuvants: Rescuing Antibiotics from Resistance
Wright, G. D. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.009 · Cited by 604
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Bacterial resistance to antibiotics: Active efflux and reduced uptake
KUMAR, A., & SCHWEIZER, H. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.04.004 · Cited by 529
Metallo‐β‐lactamase structure and function
Palzkill, T. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06796.x · Cited by 505
Plant Natural Products Targeting Bacterial Virulence Factors
Silva, L. N., Zimmer, K. R., Macedo, A. J., & Trentin, D. S. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00184 · Cited by 504
Targeting Antibiotic Resistance
Chellat, M. F., Raguž, L., & Riedl, R. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201506818 · Cited by 487
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Hecker, S. J., Reddy, K. R., Totrov, M., Hirst, G. C., Lomovskaya, O., Griffith, D. C., King, P., Tsivkovski, R., Sun, D., Sabet, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00127 · Cited by 422
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Durand-Réville, T. F., Lahiri, S., Thresher, J., Livchak, S., Gao, N., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485979 · Cited by 372
Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?
Brown, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4675 · Cited by 359
Antibiotic Adjuvants: Diverse Strategies for Controlling Drug‐Resistant Pathogens
Gill, E. E., Franco, O. L., & Hancock, R. E. W. (2015) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12478 · Cited by 319
Lamers, R. P., Cavallari, J. F., & Burrows, L. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060666 · Cited by 291
New β-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World
Drawz, S. M., Papp-Wallace, K. M., & Bonomo, R. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00826-13 · Cited by 286
Durand-Réville, T. F., Guler, S., Comita-Prevoir, J., Chen, B., Bifulco, N., Huynh, H., Lahiri, S., Shapiro, A. B., McLeod, S. M., Carter, N. M., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.104 · Cited by 285
Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy
Mahamoud, A., Chevalier, J., Alibert-Franco, S., Kern, W. V., & Pagès, J.-M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl493 · Cited by 270
The Challenge of Overcoming Antibiotic Resistance: An Adjuvant Approach?
Melander, R. J., & Melander, C. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00071 · Cited by 250
Antibiotic adjuvants: multicomponent anti-infective strategies
Kalan, L., & Wright, G. D. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399410001766 · Cited by 249
Antibiotics in late clinical development
Fernandes, P., & Martens, E. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.025 · Cited by 247
Antibiotic treatment enhances the genome-wide mutation rate of target cells
Long, H., Miller, S. F., Strauss, C., Zhao, C., Cheng, L., Ye, Z., Griffin, K., Te, R., Lee, H., Chen, C.-C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601208113 · Cited by 208
Morinaka, A., Tsutsumi, Y., Yamada, M., Suzuki, K., Watanabe, T., Abe, T., Furuuchi, T., Inamura, S., Sakamaki, Y., Mitsuhashi, N., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv166 · Cited by 183
Inhibitors of Multidrug Resistant Efflux Systems in Bacteria
Zechini, B., & Versace, I. (2009) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/157489109787236256 · Cited by 172
Lagacé-Wiens, P., Walkty, A., & Karlowsky, J. (2014) · Core Evidence · doi:10.2147/ce.s40698 · Cited by 169
The inhibition of class C β-lactamases by boronic acids
Beesley, T., Gascoyne, N., Knott-Hunziker, V, Petursson, S., Waley, S. G., Jaurin, B., & Grundström, T. (1983) · Biochemical Journal · doi:10.1042/bj2090229 · Cited by 159
Microbial Efflux Pump Inhibition: Tactics and Strategies
Tegos, G. P., Haynes, M. K., Strouse, J. J., Khan, M. M. T., Bologa, C., Oprea, T. I., & Sklar, L. A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795703726 · Cited by 158
Chemical Strategies To Target Bacterial Virulence
Garland, M., Loscher, S., & Bogyo, M. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00676 · Cited by 147
Reversible inhibitors of penicillinases
Kiener, P. A., & Waley, S. G. (1978) · Biochemical Journal · doi:10.1042/bj1690197 · Cited by 139
Current Advances in Developing Inhibitors of Bacterial Multidrug Efflux Pumps
Mahmood, H. Y., Jamshidi, S., Sutton, J. M., & Rahman, K. M. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160304150522 · Cited by 136
Nanomolar Inhibitors of AmpC β-Lactamase
Morandi, F., Caselli, E., Morandi, S., Focia, P. J., Blázquez, J., Shoichet, B. K., & Prati, F. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0288338 · Cited by 130
Abdali, N., Parks, J. M., Haynes, K. M., Chaney, J. L., Green, A. T., Wolloscheck, D., Walker, J. K., Rybenkov, V. V., Baudry, J. Y., Smith, J. C., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00167 · Cited by 127
Kostyanev, T., Bonten, M. J. M., O'Brien, S., Steel, H. M., Ross, S., François, B., Tacconelli, E., Winterhalter, M., Stavenger, R. A., Karlén, A., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv339 · Cited by 126
Class D β-Lactamases: A Reappraisal after Five Decades
Leonard, D. A., Bonomo, R. A., & Powers, R. A. (2013) · Accounts of Chemical Research · doi:10.1021/ar300327a · Cited by 123
Li, C., Budge, L. P., Driscoll, C. D., Willardson, B. M., Allman, G. W., & Savage, P. B. (1999) · Journal of the American Chemical Society · doi:10.1021/ja982938m · Cited by 122
Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition
King, D. T., King, A. M., Lal, S. M., Wright, G. D., & Strynadka, N. C. J. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00007 · Cited by 113
Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach
Rex, J. H., & Outterson, K. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00500-9 · Cited by 113
Lahiri, S. D., Mangani, S., Jahić, H., Benvenuti, M., Durand-Réville, T. F., Luca, F. D., Ehmann, D. E., Rossolini, G. M., Alm, R. A., & Docquier, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500703p · Cited by 109
Time for a change: addressing R&D and commercialization challenges for antibacterials
Payne, D. J., Miller, L. F., Findlay, D. M., Anderson, J., & Marks, L. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0086 · Cited by 102
Polyamines Increase Antibiotic Susceptibility in Pseudomonas aeruginosa
Kwon, D. H., & Lu, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.5.1623-1627.2006 · Cited by 102
Antibiotic adjuvants: identification and clinical use
Bernal, P., Molina‐Santiago, C., Daddaoua, A., & Llamas, M. A. (2013) · Microbial Biotechnology · doi:10.1111/1751-7915.12044 · Cited by 101
Evaluation of Multidrug Efflux Pump Inhibitors by a New Method Using Microfluidic Channels
Matsumoto, Y., Hayama, K., Sakakihara, S., Nishino, K., Noji, H., Iino, R., & Yamaguchi, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018547 · Cited by 101
In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor
Coleman, K., Griffin, D. R., Page, J., & Upshon, P. A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.9.1580 · Cited by 96
Energetic, structural, and antimicrobial analyses of β-lactam side chain recognition by β-lactamases
Caselli, E., Powers, R. A., Blasczcak, L. C., Wu, C. Y. E., Prati, F., & Shoichet, B. K. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00052-1 · Cited by 87
Understanding efflux in Gram-negative bacteria: opportunities for drug discovery
Schweizer, H. P. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.688949 · Cited by 84
Insights into Newer Antimicrobial Agents against Gram-negative Bacteria
Yaneja, N., & Kaur, H. (2016) · Microbiology Insights · doi:10.4137/mbi.s29459 · Cited by 82
Schneider, K. D., Ortega, C. J., Renck, N. A., Bonomo, R. A., Powers, R. A., & Leonard, D. A. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.12.042 · Cited by 78
Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo
Eidam, O., Romagnoli, C., Dalmasso, G., Barelier, S., Caselli, E., Bonnet, R., Shoichet, B. K., & Prati, F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208337109 · Cited by 77
Bacterial Iron Uptake Pathways: Gates for the Import of Bactericide Compounds
Schalk, I. J., & Mislin, G. L. A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00554 · Cited by 72
Bou, G., Santillana, E., Sheri, A., Beceiro, A., Sampson, J. M., Kalp, M., Bethel, C. R., Distler, A. M., Drawz, S. M., Pagadala, S. R. R., et al. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104092z · Cited by 68
King, A. M., King, D. T., French, S., Brouillette, É., Asli, A., Alexander, J. A. N., Vuckovic, M., Maiti, S. N., Parr, T. R., Brown, E. D., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00944 · Cited by 60
Strategic Design of an Effective β-Lactamase Inhibitor
Pattanaik, P., Bethel, C. R., Hujer, A. M., Hujer, K. M., Distler, A. M., Taracila, M. A., Anderson, V. E., Fritsche, T. R., Jones, R. N., Pagadala, S. R. R., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806833200 · Cited by 56
Discovery of antibiotic adjuvants
Farha, M. A., & Brown, E. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2500 · Cited by 52
Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check
Bush, K. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00100 · Cited by 52
Chen, Y. L., Chang, C.-W., & HEDBERG, K. (1986) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)84819-4 · Cited by 49
Goldstein, E. J. C., Citron, D. M., Tyrrell, K. L., & Merriam, C. V. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02418-12 · Cited by 45
The global challenge of new classes of antibacterial agents: an industry perspective
FERNANDES, P. B. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.06.003 · Cited by 44
Vázquez-Ucha, J. C., Maneiro, M., Martínez-Guitián, M., Buynak, J. D., Bethel, C. R., Bonomo, R. A., Bou, G., Poza, M., González‐Bello, C., & Beceiro, A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01172-17 · Cited by 43
Self-citationLN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48
Vallejo, J. A., Martínez-Guitián, M., Vázquez-Ucha, J. C., González‐Bello, C., Poza, M., Buynak, J. D., Bethel, C. R., Bonomo, R. A., Bou, G., & Beceiro, A. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw105 · Cited by 40
Self-citationVandavasi, V. G., Langan, P. S., Weiss, K. L., Parks, J. M., Cooper, J. B., Ginell, S. L., & Coates, L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01636-16 · Cited by 40
Françoise Van Bambeke, A., Pagès, J., & LEE, V. J. (2010) · Cited by 27
What's old is new: Reconfiguring known antibiotics to fight drug resistance
Chakradhar, S. (2016) · Nature Medicine · doi:10.1038/nm1116-1197 · Cited by 24
Antibiotic Resistance: Who Will Pay the Bills?
Zaoutis, T. E. (2009) · Clinical Infectious Diseases · doi:10.1086/605631 · Cited by 6
Cited by
Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S., & Pardesi, K. R. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00539 · Cited by 1,644
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health
Majumder, M. A. A., Rahman, S., Cohall, D., Bharatha, A., Singh, K., Haque, M., & Gittens-St Hilaire, M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s290835 · Cited by 633
Bacterial defences: mechanisms, evolution and antimicrobial resistance
Smith, W. P. J., Wucher, B. R., Nadell, C. D., & Foster, K. R. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00877-3 · Cited by 385
Antibiotic resistance breakers: current approaches and future directions
Laws, M., Shaaban, A., & Rahman, K. M. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz014 · Cited by 356
Metadata
- Authors
- González-Bello, C.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 27
- Issue
- 18
- Pages
- 4221-4228
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2750414851
- Cited by
- 254
- References
- 79
- FWCI
- 8.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.